TransCode Therapeutics, Inc. (RNAZ)

TransCode Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1.88	2.77	4.97	20.83	0.83	0.2
Short-Term Investments	-	-	0.01	0.01	0	-
Cash & Short-Term Investments	1.88	2.77	4.98	20.84	0.83	0.2
Cash Growth	-74.83%	-44.40%	-76.11%	2406.60%	306.52%	-4.00%
Prepaid Expenses	0.53	0.55	1.38	1.46	-	-
Other Current Assets	1.21	1.14	1.02	0.44	-	-
Total Current Assets	3.61	4.46	7.38	22.73	0.83	0.2
Property, Plant & Equipment	0.21	0.6	0.21	0.21	-	-
Long-Term Deferred Charges	-	-	-	-	0.22	-
Other Long-Term Assets	0.11	0.11	-	-	-	-
Total Assets	3.94	5.17	7.59	22.94	1.06	0.2
Accrued Expenses	2.13	3.05	4.35	2.5	0.4	0.06
Current Portion of Leases	0.15	0.41	-	-	-	-
Current Unearned Revenue	-	0.03	-	0.03	-	-
Total Current Liabilities	2.28	3.49	4.35	2.53	0.4	0.06
Long-Term Debt	-	-	-	-	2.09	0.93
Long-Term Leases	-	0.04	-	-	-	-
Other Long-Term Liabilities	-	-	-	-	1.97	0.32
Total Liabilities	2.28	3.53	4.35	2.53	4.46	1.31
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	58.91	48.06	31.11	30.71	0.07	0.02
Retained Earnings	-57.26	-46.42	-27.87	-10.31	-3.46	-1.12
Comprehensive Income & Other	-	-	-	-	-0.01	-0.01
Shareholders' Equity	1.65	1.64	3.24	20.4	-3.41	-1.11
Total Liabilities & Equity	3.94	5.17	7.59	22.94	1.06	0.2
Total Debt	0.15	0.45	-	-	2.09	0.93
Net Cash (Debt)	1.72	2.32	4.98	20.84	-1.26	-0.72
Net Cash Growth	-74.87%	-53.45%	-76.11%	-	-	-
Filing Date Shares Outstanding	0.52	0.18	-	-	-	-
Total Common Shares Outstanding	0.52	0.02	-	-	-	-
Working Capital	1.33	0.96	3.03	20.2	0.43	0.14
Book Value Per Share	3.16	86.30	-	-	-	-
Tangible Book Value	1.65	1.64	3.24	20.4	-3.41	-1.11
Tangible Book Value Per Share	3.16	86.30	-	-	-	-
Machinery	0.41	0.38	0.35	0.25	-	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q